Stéphane Brézillon Selected Research

Small Leucine-Rich Proteoglycans

11/2021	Assessment of Ovarian Tumor Growth in Wild-Type and Lumican-Deficient Mice: Insights Using Infrared Spectral Imaging, Histopathology, and Immunohistochemistry.
9/2021	Differential MMP-14 Targeting by Lumican-Derived Peptides Unraveled by In Silico Approach.
11/2020	Evaluation of lumican effects on morphology of invading breast cancer cells, expression of integrins and downstream signaling.
1/2020	Label-Free Infrared Spectral Histology of Skin Tissue Part II: Impact of a Lumican-Derived Peptide on Melanoma Growth.
1/2016	Lumican Inhibits SNAIL-Induced Melanoma Cell Migration Specifically by Blocking MMP-14 Activity.
1/2013	Lumican - derived peptides inhibit melanoma cell growth and migration.
10/2010	Lumican inhibits cell migration through α2β1 integrin.
9/2009	Lumican core protein inhibits melanoma cell migration via alterations of focal adhesion complexes.
11/2008	Lumican affects actin cytoskeletal organization in human melanoma A375 cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stéphane Brézillon Research Topics

Disease

20	Neoplasms (Cancer) 11/2021 - 11/2008
16	Melanoma (Melanoma, Malignant) 11/2021 - 12/2007
5	Breast Neoplasms (Breast Cancer) 11/2020 - 01/2017
3	Neoplasm Metastasis (Metastasis) 01/2021 - 05/2013
2	Inflammatory Breast Neoplasms 09/2020 - 12/2018
2	Colonic Neoplasms (Colon Cancer) 01/2020 - 01/2016
1	Ovarian Neoplasms (Ovarian Cancer) 11/2021
1	Ovarian Epithelial Carcinoma 11/2021
1	Acidosis 01/2020
1	Hypoxia (Hypoxemia) 01/2020
1	Wounds and Injuries (Trauma) 01/2018
1	Heart Failure 01/2017
1	Disease Progression 01/2017
1	Experimental Melanoma 01/2017
1	Pulmonary Hypertension 08/2016
1	Ascites 08/2016
1	Carcinogenesis 05/2013

Drug/Important Bio-Agent (IBA)

21	LumicanIBA 11/2021 - 12/2007
9	Small Leucine-Rich ProteoglycansIBA 11/2021 - 11/2008
7	CollagenIBA 11/2021 - 01/2012
7	Proteins (Proteins, Gene)FDA Link 01/2020 - 12/2007
6	Peptides (Polypeptides)IBA 09/2021 - 09/2009
5	IntegrinsIBA 11/2021 - 12/2007
5	Matrix Metalloproteinases (MMPs)IBA 01/2021 - 01/2013
5	Biomarkers (Surrogate Marker)IBA 09/2020 - 01/2017
4	lumcorinIBA 09/2021 - 09/2009
3	Estrogen ReceptorsIBA 11/2020 - 01/2017
2	AntibodiesIBA 11/2021 - 01/2020
2	Amino Acids FDA Link 09/2021 - 01/2013
2	Proteoglycans (Proteoglycan)IBA 09/2020 - 01/2017
2	Small Interfering RNA (siRNA)IBA 08/2020 - 10/2010
2	EnzymesIBA 08/2020 - 01/2020
2	Methionine (L-Methionine)FDA Link 01/2017 - 08/2016
2	CopperIBA 01/2017 - 08/2016
2	Matrix Metalloproteinase 2 (Gelatinase A)IBA 01/2017 - 08/2016
2	Integrin beta1IBA 09/2009 - 01/2008
1	C.I. direct red 80IBA 11/2021
1	Cyclin D1IBA 11/2021
1	Matrix Metalloproteinase 14 (MT1-MMP)IBA 01/2021
1	GlycosaminoglycansIBA 09/2020
1	Cadherins (E-Cadherin)IBA 08/2020
1	Heparitin Sulfate (Heparan Sulfate)IBA 08/2020
1	Peptide Hydrolases (Proteases)FDA Link 01/2020
1	Oxygen (Dioxygen)IBA 01/2020
1	ProteomeIBA 01/2020
1	Caspase 3 (Caspase-3)IBA 01/2020
1	Messenger RNA (mRNA)IBA 01/2020
1	GlypicansIBA 01/2020
1	Transcription Factors (Transcription Factor)IBA 01/2020
1	Free RadicalsIBA 01/2020
1	Pharmaceutical PreparationsIBA 01/2018
1	TAX2 peptideIBA 01/2017
1	DecorinIBA 11/2014
1	AgarIBA 01/2013
1	Extracellular Matrix ProteinsIBA 10/2010
1	Collagen Type I (Type I Collagen)IBA 09/2009
1	Fibronectins (Fibronectin)IBA 09/2009
1	Leucine (L-Leucine)FDA Link 09/2009
1	Protein Isoforms (Isoforms)IBA 11/2008
1	Biological ProductsIBA 11/2008
1	Divalent CationsIBA 01/2008

Therapy/Procedure

2	Therapeutics 01/2020 - 01/2017
1	Intravenous Injections 01/2021
1	Synchrotrons 09/2020
1	Subcutaneous Injections 01/2012